APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multi-Cancer Early Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multi-Cancer Early Screening Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchMulti-Cancer Early Screening Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Multi-Cancer Early Screening Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Multi-Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multi-Cancer Early Screening Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Multi-Cancer Early Screening Market Analysis and Forecast 2026-2032222 pages · $4,950 USD

Market perspective

The global Multi-Cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multi-Cancer Early Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multi-Cancer Early Screening market include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Multi-Cancer Early Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multi-Cancer Early Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multi-Cancer Early Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Multi-Cancer Early Screening market.

Multi-Cancer Early Screening Segment by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

BGI Genomics

Burning Rock Biotech Limited

New Horizon Health Limited

Yeasen Bio

Hangzhou Aoru Biotech

Amoy Diagnostics Co., Ltd.

Genetron Health

AnchorDx

Surexam Bio-Tech Co.,Ltd.

HaploX

HefeiLaierBiotechnologyCo.,Ltd

Multi-Cancer Early Screening Segment by Type

cfDNA Methylation

Low-pass WGS

Protein Marker Combination

Multi-omics Integrated Analysis

Multi-Cancer Early Screening Segment by Application

Medical Institutions

Physical Examination Centers

Multi-Cancer Early Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Multi-Cancer Early Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Multi-Cancer Early Screening key companies, revenue, market share, and recent developments.

3. To split the Multi-Cancer Early Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Multi-Cancer Early Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multi-Cancer Early Screening significant trends, drivers, influence factors in global and regions.

6. To analyze Multi-Cancer Early Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multi-Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-Cancer Early Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multi-Cancer Early Screening industry.

Chapter 3: Detailed analysis of Multi-Cancer Early Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Multi-Cancer Early Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Multi-Cancer Early Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multi-Cancer Early Screening Industry Trends Table 2. Multi-Cancer Early Screening Industry Drivers Table 3. Multi-Cancer Early Screening Industry Opportunities and Challenges Table 4. Multi-Cancer Early Screening Industry Restraints Table 5. Global Multi-Cancer Early Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multi-Cancer Early Screening Revenue Share by Company (2021-2026) Table 7. Global Multi-Cancer Early Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Multi-Cancer Early Screening Key Company Manufacturing Base & Headquarters Table 9. Global Multi-Cancer Early Screening Company, Product Type & Application Table 10. Global Multi-Cancer Early Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Multi-Cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of cfDNA Methylation Table 15. Significant Companies of Low-pass WGS Table 16. Significant Companies of Protein Marker Combination Table 17. Significant Companies of Multi-omics Integrated Analysis Table 18. Global Multi-Cancer Early Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Multi-Cancer Early Screening Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Multi-Cancer Early Screening Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Multi-Cancer Early Screening Sales Value Share by Type (2021-2026) Table 22. Global Multi-Cancer Early Screening Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Medical Institutions Table 24. Significant Companies of Physical Examination Centers Table 25. Global Multi-Cancer Early Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Multi-Cancer Early Screening Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Multi-Cancer Early Screening Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Multi-Cancer Early Screening Sales Value Share by Application (2021-2026) Table 29. Global Multi-Cancer Early Screening Sales Value Share by Application (2027-2032) Table 30. Global Multi-Cancer Early Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Multi-Cancer Early Screening Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Multi-Cancer Early Screening Sales Value Share by Region (2021-2026) Table 33. Global Multi-Cancer Early Screening Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Multi-Cancer Early Screening Sales Value Share by Region (2027-2032) Table 35. Global Multi-Cancer Early Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Multi-Cancer Early Screening Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Multi-Cancer Early Screening Sales Value Market Share by Country (2021-2026) Table 38. Global Multi-Cancer Early Screening Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Multi-Cancer Early Screening Sales Value Market Share by Country (2027-2032) Table 40. Guardant Health Company Information Table 41. Guardant Health Business Overview Table 42. Guardant Health Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Guardant Health Multi-Cancer Early Screening Product Portfolio Table 44. Guardant Health Recent Development Table 45. Exact Sciences Company Information Table 46. Exact Sciences Business Overview Table 47. Exact Sciences Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Exact Sciences Multi-Cancer Early Screening Product Portfolio Table 49. Exact Sciences Recent Development Table 50. Freenome Company Information Table 51. Freenome Business Overview Table 52. Freenome Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Freenome Multi-Cancer Early Screening Product Portfolio Table 54. Freenome Recent Development Table 55. Epiginomics AG Company Information Table 56. Epiginomics AG Business Overview Table 57. Epiginomics AG Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Epiginomics AG Multi-Cancer Early Screening Product Portfolio Table 59. Epiginomics AG Recent Development Table 60. Bio-techne Company Information Table 61. Bio-techne Business Overview Table 62. Bio-techne Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Bio-techne Multi-Cancer Early Screening Product Portfolio Table 64. Bio-techne Recent Development Table 65. ThriveEarlier Detection Company Information Table 66. ThriveEarlier Detection Business Overview Table 67. ThriveEarlier Detection Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. ThriveEarlier Detection Multi-Cancer Early Screening Product Portfolio Table 69. ThriveEarlier Detection Recent Development Table 70. GRAIL, Inc. Company Information Table 71. GRAIL, Inc. Business Overview Table 72. GRAIL, Inc. Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. GRAIL, Inc. Multi-Cancer Early Screening Product Portfolio Table 74. GRAIL, Inc. Recent Development Table 75. CellMax life Company Information Table 76. CellMax life Business Overview Table 77. CellMax life Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. CellMax life Multi-Cancer Early Screening Product Portfolio Table 79. CellMax life Recent Development Table 80. Berry Genomics Company Information Table 81. Berry Genomics Business Overview Table 82. Berry Genomics Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Berry Genomics Multi-Cancer Early Screening Product Portfolio Table 84. Berry Genomics Recent Development Table 85. Singlera Genomics Company Information Table 86. Singlera Genomics Business Overview Table 87. Singlera Genomics Multi-Cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Singlera Genomics Multi-Cancer Early Screening Product Portfolio Table 89. Singlera Genomics Recent Development Table 90. Geneseeq Company Information Table 91. Geneseeq Business Overview Table 92. Geneseeq Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Geneseeq Multi-Cancer Early Screening Product Portfolio Table 94. Geneseeq Recent Development Table 95. BGI Genomics Company Information Table 96. BGI Genomics Business Overview Table 97. BGI Genomics Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. BGI Genomics Multi-Cancer Early Screening Product Portfolio Table 99. BGI Genomics Recent Development Table 100. Burning Rock Biotech Limited Company Information Table 101. Burning Rock Biotech Limited Business Overview Table 102. Burning Rock Biotech Limited Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Burning Rock Biotech Limited Multi-Cancer Early Screening Product Portfolio Table 104. Burning Rock Biotech Limited Recent Development Table 105. New Horizon Health Limited Company Information Table 106. New Horizon Health Limited Business Overview Table 107. New Horizon Health Limited Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. New Horizon Health Limited Multi-Cancer Early Screening Product Portfolio Table 109. New Horizon Health Limited Recent Development Table 110. Yeasen Bio Company Information Table 111. Yeasen Bio Business Overview Table 112. Yeasen Bio Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Yeasen Bio Multi-Cancer Early Screening Product Portfolio Table 114. Yeasen Bio Recent Development Table 115. Hangzhou Aoru Biotech Company Information Table 116. Hangzhou Aoru Biotech Business Overview Table 117. Hangzhou Aoru Biotech Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Hangzhou Aoru Biotech Multi-Cancer Early Screening Product Portfolio Table 119. Hangzhou Aoru Biotech Recent Development Table 120. Amoy Diagnostics Co., Ltd. Company Information Table 121. Amoy Diagnostics Co., Ltd. Business Overview Table 122. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Product Portfolio Table 124. Amoy Diagnostics Co., Ltd. Recent Development Table 125. Genetron Health Company Information Table 126. Genetron Health Business Overview Table 127. Genetron Health Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Genetron Health Multi-Cancer Early Screening Product Portfolio Table 129. Genetron Health Recent Development Table 130. AnchorDx Company Information Table 131. AnchorDx Business Overview Table 132. AnchorDx Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. AnchorDx Multi-Cancer Early Screening Product Portfolio Table 134. AnchorDx Recent Development Table 135. Surexam Bio-Tech Co.,Ltd. Company Information Table 136. Surexam Bio-Tech Co.,Ltd. Business Overview Table 137. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Product Portfolio Table 139. Surexam Bio-Tech Co.,Ltd. Recent Development Table 140. HaploX Company Information Table 141. HaploX Business Overview Table 142. HaploX Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. HaploX Multi-Cancer Early Screening Product Portfolio Table 144. HaploX Recent Development Table 145. HefeiLaierBiotechnologyCo.,Ltd Company Information Table 146. HefeiLaierBiotechnologyCo.,Ltd Business Overview Table 147. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 148. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Product Portfolio Table 149. HefeiLaierBiotechnologyCo.,Ltd Recent Development Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Multi-Cancer Early Screening Product Image Figure 2. Global Multi-Cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global Multi-Cancer Early Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. cfDNA Methylation Image Figure 8. Low-pass WGS Image Figure 9. Protein Marker Combination Image Figure 10. Multi-omics Integrated Analysis Image Figure 11. Global Multi-Cancer Early Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Multi-Cancer Early Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Multi-Cancer Early Screening Sales Value Share by Type (2021-2032) Figure 14. Medical Institutions Image Figure 15. Physical Examination Centers Image Figure 16. Global Multi-Cancer Early Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Multi-Cancer Early Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Multi-Cancer Early Screening Sales Value Share by Application (2021-2032) Figure 19. Global Multi-Cancer Early Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Multi-Cancer Early Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Multi-Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 22. North America Multi-Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Multi-Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Multi-Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Multi-Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Multi-Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Multi-Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 28. South America Multi-Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Multi-Cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Multi-Cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • cfDNA Methylation
  • Low-pass WGS
  • Protein Marker Combination
  • Multi-omics Integrated Analysis
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • BGI Genomics
  • Burning Rock Biotech Limited
  • New Horizon Health Limited
  • Yeasen Bio
  • Hangzhou Aoru Biotech
  • Amoy Diagnostics Co., Ltd.
  • Genetron Health
  • AnchorDx
  • Surexam Bio-Tech Co.,Ltd.
  • HaploX
  • HefeiLaierBiotechnologyCo.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multi-Cancer Early Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multi-Cancer Early Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Multi-Cancer Early Screening Market Dynamics
  1. 2.1 Multi-Cancer Early Screening Industry Trends
  2. 2.2 Multi-Cancer Early Screening Industry Drivers
  3. 2.3 Multi-Cancer Early Screening Industry Opportunities and Challenges
  4. 2.4 Multi-Cancer Early Screening Industry Restraints
3 Multi-Cancer Early Screening Market by Company
  1. 3.1 Global Multi-Cancer Early Screening Company Revenue Ranking in 2025
  2. 3.2 Global Multi-Cancer Early Screening Revenue by Company (2021-2026)
  3. 3.3 Global Multi-Cancer Early Screening Company Ranking (2024-2026)
  4. 3.4 Global Multi-Cancer Early Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global Multi-Cancer Early Screening Company Product Type and Application
  6. 3.6 Global Multi-Cancer Early Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Multi-Cancer Early Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Multi-Cancer Early Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Multi-Cancer Early Screening Market by Type
  1. 4.1 Multi-Cancer Early Screening Type Introduction
  2. 4.1.1 cfDNA Methylation
  3. 4.1.2 Low-pass WGS
  4. 4.1.3 Protein Marker Combination
  5. 4.1.4 Multi-omics Integrated Analysis
  6. 4.2 Global Multi-Cancer Early Screening Sales Value by Type
  7. 4.2.1 Global Multi-Cancer Early Screening Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Multi-Cancer Early Screening Sales Value by Type (2021-2032)
  9. 4.2.3 Global Multi-Cancer Early Screening Sales Value Share by Type (2021-2032)
5 Multi-Cancer Early Screening Market by Application
  1. 5.1 Multi-Cancer Early Screening Application Introduction
  2. 5.1.1 Medical Institutions
  3. 5.1.2 Physical Examination Centers
  4. 5.2 Global Multi-Cancer Early Screening Sales Value by Application
  5. 5.2.1 Global Multi-Cancer Early Screening Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multi-Cancer Early Screening Sales Value by Application (2021-2032)
  7. 5.2.3 Global Multi-Cancer Early Screening Sales Value Share by Application (2021-2032)
6 Multi-Cancer Early Screening Regional Value Analysis
  1. 6.1 Global Multi-Cancer Early Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multi-Cancer Early Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global Multi-Cancer Early Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global Multi-Cancer Early Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multi-Cancer Early Screening Sales Value (2021-2032)
  7. 6.3.2 North America Multi-Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Multi-Cancer Early Screening Sales Value (2021-2032)
  10. 6.4.2 Europe Multi-Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Multi-Cancer Early Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Multi-Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Multi-Cancer Early Screening Sales Value (2021-2032)
  16. 6.6.2 South America Multi-Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Multi-Cancer Early Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Multi-Cancer Early Screening Sales Value Share by Country, 2025 VS 2032
7 Multi-Cancer Early Screening Country-level Value Analysis
  1. 7.1 Global Multi-Cancer Early Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multi-Cancer Early Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global Multi-Cancer Early Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global Multi-Cancer Early Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Multi-Cancer Early Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Multi-Cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Multi-Cancer Early Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Guardant Health
  2. 8.1.1 Guardant Health Company Information
  3. 8.1.2 Guardant Health Business Overview
  4. 8.1.3 Guardant Health Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Guardant Health Multi-Cancer Early Screening Product Portfolio
  6. 8.1.5 Guardant Health Recent Developments
  7. 8.2 Exact Sciences
  8. 8.2.1 Exact Sciences Company Information
  9. 8.2.2 Exact Sciences Business Overview
  10. 8.2.3 Exact Sciences Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Exact Sciences Multi-Cancer Early Screening Product Portfolio
  12. 8.2.5 Exact Sciences Recent Developments
  13. 8.3 Freenome
  14. 8.3.1 Freenome Company Information
  15. 8.3.2 Freenome Business Overview
  16. 8.3.3 Freenome Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Freenome Multi-Cancer Early Screening Product Portfolio
  18. 8.3.5 Freenome Recent Developments
  19. 8.4 Epiginomics AG
  20. 8.4.1 Epiginomics AG Company Information
  21. 8.4.2 Epiginomics AG Business Overview
  22. 8.4.3 Epiginomics AG Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Epiginomics AG Multi-Cancer Early Screening Product Portfolio
  24. 8.4.5 Epiginomics AG Recent Developments
  25. 8.5 Bio-techne
  26. 8.5.1 Bio-techne Company Information
  27. 8.5.2 Bio-techne Business Overview
  28. 8.5.3 Bio-techne Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-techne Multi-Cancer Early Screening Product Portfolio
  30. 8.5.5 Bio-techne Recent Developments
  31. 8.6 ThriveEarlier Detection
  32. 8.6.1 ThriveEarlier Detection Company Information
  33. 8.6.2 ThriveEarlier Detection Business Overview
  34. 8.6.3 ThriveEarlier Detection Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ThriveEarlier Detection Multi-Cancer Early Screening Product Portfolio
  36. 8.6.5 ThriveEarlier Detection Recent Developments
  37. 8.7 GRAIL, Inc.
  38. 8.7.1 GRAIL, Inc. Company Information
  39. 8.7.2 GRAIL, Inc. Business Overview
  40. 8.7.3 GRAIL, Inc. Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GRAIL, Inc. Multi-Cancer Early Screening Product Portfolio
  42. 8.7.5 GRAIL, Inc. Recent Developments
  43. 8.8 CellMax life
  44. 8.8.1 CellMax life Company Information
  45. 8.8.2 CellMax life Business Overview
  46. 8.8.3 CellMax life Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CellMax life Multi-Cancer Early Screening Product Portfolio
  48. 8.8.5 CellMax life Recent Developments
  49. 8.9 Berry Genomics
  50. 8.9.1 Berry Genomics Company Information
  51. 8.9.2 Berry Genomics Business Overview
  52. 8.9.3 Berry Genomics Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Berry Genomics Multi-Cancer Early Screening Product Portfolio
  54. 8.9.5 Berry Genomics Recent Developments
  55. 8.10 Singlera Genomics
  56. 8.10.1 Singlera Genomics Company Information
  57. 8.10.2 Singlera Genomics Business Overview
  58. 8.10.3 Singlera Genomics Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Singlera Genomics Multi-Cancer Early Screening Product Portfolio
  60. 8.10.5 Singlera Genomics Recent Developments
  61. 8.11 Geneseeq
  62. 8.11.1 Geneseeq Company Information
  63. 8.11.2 Geneseeq Business Overview
  64. 8.11.3 Geneseeq Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Geneseeq Multi-Cancer Early Screening Product Portfolio
  66. 8.11.5 Geneseeq Recent Developments
  67. 8.12 BGI Genomics
  68. 8.12.1 BGI Genomics Company Information
  69. 8.12.2 BGI Genomics Business Overview
  70. 8.12.3 BGI Genomics Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BGI Genomics Multi-Cancer Early Screening Product Portfolio
  72. 8.12.5 BGI Genomics Recent Developments
  73. 8.13 Burning Rock Biotech Limited
  74. 8.13.1 Burning Rock Biotech Limited Company Information
  75. 8.13.2 Burning Rock Biotech Limited Business Overview
  76. 8.13.3 Burning Rock Biotech Limited Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Burning Rock Biotech Limited Multi-Cancer Early Screening Product Portfolio
  78. 8.13.5 Burning Rock Biotech Limited Recent Developments
  79. 8.14 New Horizon Health Limited
  80. 8.14.1 New Horizon Health Limited Company Information
  81. 8.14.2 New Horizon Health Limited Business Overview
  82. 8.14.3 New Horizon Health Limited Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  83. 8.14.4 New Horizon Health Limited Multi-Cancer Early Screening Product Portfolio
  84. 8.14.5 New Horizon Health Limited Recent Developments
  85. 8.15 Yeasen Bio
  86. 8.15.1 Yeasen Bio Company Information
  87. 8.15.2 Yeasen Bio Business Overview
  88. 8.15.3 Yeasen Bio Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Yeasen Bio Multi-Cancer Early Screening Product Portfolio
  90. 8.15.5 Yeasen Bio Recent Developments
  91. 8.16 Hangzhou Aoru Biotech
  92. 8.16.1 Hangzhou Aoru Biotech Company Information
  93. 8.16.2 Hangzhou Aoru Biotech Business Overview
  94. 8.16.3 Hangzhou Aoru Biotech Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hangzhou Aoru Biotech Multi-Cancer Early Screening Product Portfolio
  96. 8.16.5 Hangzhou Aoru Biotech Recent Developments
  97. 8.17 Amoy Diagnostics Co., Ltd.
  98. 8.17.1 Amoy Diagnostics Co., Ltd. Company Information
  99. 8.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  100. 8.17.3 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Product Portfolio
  102. 8.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
  103. 8.18 Genetron Health
  104. 8.18.1 Genetron Health Company Information
  105. 8.18.2 Genetron Health Business Overview
  106. 8.18.3 Genetron Health Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Genetron Health Multi-Cancer Early Screening Product Portfolio
  108. 8.18.5 Genetron Health Recent Developments
  109. 8.19 AnchorDx
  110. 8.19.1 AnchorDx Company Information
  111. 8.19.2 AnchorDx Business Overview
  112. 8.19.3 AnchorDx Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  113. 8.19.4 AnchorDx Multi-Cancer Early Screening Product Portfolio
  114. 8.19.5 AnchorDx Recent Developments
  115. 8.20 Surexam Bio-Tech Co.,Ltd.
  116. 8.20.1 Surexam Bio-Tech Co.,Ltd. Company Information
  117. 8.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
  118. 8.20.3 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Product Portfolio
  120. 8.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
  121. 8.21 HaploX
  122. 8.21.1 HaploX Company Information
  123. 8.21.2 HaploX Business Overview
  124. 8.21.3 HaploX Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  125. 8.21.4 HaploX Multi-Cancer Early Screening Product Portfolio
  126. 8.21.5 HaploX Recent Developments
  127. 8.22 HefeiLaierBiotechnologyCo.,Ltd
  128. 8.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Information
  129. 8.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
  130. 8.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Revenue and Gross Margin (2021-2026)
  131. 8.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Product Portfolio
  132. 8.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst